[18F]VM4-037 MicroPET Imaging and Biodistribution of Two In Vivo CAIX-Expressing Tumor Models

Molecular Imaging and Biology

Volumn 17, Issue 5, 2015, Pages 615-619

  Peeters, Sarah G J A ^a   Dubois, Ludwig ^a   Lieuwes, Natasja G ^a   Laan, Dennis ^b   Mooijer, Martien ^b   Schuit, Robert C ^b   Vullo, Daniela ^c   Supuran, Claudiu T ^c   Eriksson, Jonas ^b   Windhorst, Albert D ^b   Lambin, Philippe ^a  

^a MAASTRICHT UNIVERSITY   (Netherlands)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^c UNIVERSITY OF FLORENCE   (Italy)

Author keywords

Biodistribution; CAIX; PET imaging; Preclinical; 18F VM4 037

Indexed keywords

3 [4 [2 (FLUROETHOXY)PHENYL] 2 [3 METHYL 2 [4 [(2 SULFAMOYLBENZO[D]THIAZOL 6 YLOXY)METHYL] 1H 1,2,3 TRIAZOL 1 YL]BUTANAMIDO]]PROPANOIC ACID F 18; CARBONATE DEHYDRATASE IX; FLUORODEOXYGLUCOSE F 18; PROPIONIC ACID DERIVATIVE; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG; 3-(4-(2-FLUOROETHOXY)PHENYL)-2-(3-METHYL-2-(4-((2-SULFAMOYLBENZO(D)THIAZOL-6-YLOXY)METHYL)-1H-1,2,3-TRIAZOL-1-YL)BUTANAMIDO)PROPANOIC ACID; CA9 PROTEIN, HUMAN; CARBONATE DEHYDRATASE; DIPEPTIDE; SULFONAMIDE; TUMOR ANTIGEN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOACCUMULATION; CONTROLLED STUDY; DRUG UPTAKE; HUMAN; HUMAN CELL; ISOTOPE LABELING; MOUSE; NONHUMAN; PET SCANNER; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN EXPRESSION; TISSUE DISTRIBUTION; CHEMISTRY; METABOLISM; MOLECULAR IMAGING; NEOPLASM; PATHOLOGY; PROCEDURES; TUMOR CELL LINE;

ANTIGENS, NEOPLASM; CARBONIC ANHYDRASE IX; CARBONIC ANHYDRASES; CELL LINE, TUMOR; DIPEPTIDES; HUMANS; MOLECULAR IMAGING; NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY; SULFONAMIDES; TISSUE DISTRIBUTION;

EID: 84941995488     PISSN: 15361632     EISSN: 18602002     Source Type: Journal    
DOI: 10.1007/s11307-015-0831-y     Document Type: Article

References (19)

1. Wykoff CC, Beasley NJ, Watson PH et al (2000) Hypoxia-inducible expression of tumor-associated carbonic anhydrases. Cancer Res 60:7075–7083
2. Wilson WR, Hay MP (2011) Targeting hypoxia in cancer therapy. Nat Rev Cancer 11:393–410
3. Lendahl U, Lee KL, Yang H, Poellinger L (2009) Generating specificity and diversity in the transcriptional response to hypoxia. Nat Rev Genet 10:821–832
4. Svastova E, Hulikova A, Rafajova M et al (2004) Hypoxia activates the capacity of tumor-associated carbonic anhydrase IX to acidify extracellular pH. FEBS Lett 577:439–445
5. Generali D, Berruti A, Brizzi MP et al (2006) Hypoxia-inducible factor-1alpha expression predicts a poor response to primary chemoendocrine therapy and disease-free survival in primary human breast cancer. Clin Cancer Res 12:4562–4568
6. Supuran CT, Dedhar S (2012) Recent developments in targeting carbonic anhydrase IX for cancer therapeutics. Oncotarget 3:84–97
7. Dubois L, Peeters SG, van Kuijk SJ et al (2013) Targeting carbonic anhydrase IX by nitroimidazole based sulfamides enhances the therapeutic effect of tumor irradiation: a new concept of dual targeting drugs. Radiother Oncol 108:523–528
8. Dubois L, Peeters S, Lieuwes NG et al (2011) Specific inhibition of carbonic anhydrase IX activity enhances the in vivo therapeutic effect of tumor irradiation. Radiother Oncol 99:424–431
9. Pacchiano F, Carta F, McDonald PC et al (2011) Ureido-substituted benzenesulfonamides potently inhibit carbonic anhydrase IX and show antimetastatic activity in a model of breast cancer metastasis. J Med Chem 54:1896–1902
10. Svastova E, Witarski W, Csaderova L et al (2012) Carbonic anhydrase IX interacts with bicarbonate transporters in lamellipodia and increases cell migration via its catalytic domain. J Biol Chem 287:3392–3402
11. Lou Y, McDonald PC, Oloumi A et al (2011) Targeting tumor hypoxia: suppression of breast tumor growth and metastasis by novel carbonic anhydrase IX inhibitors. Cancer Res 71:3364–3376
12. Doss M, Kolb HC, Walsh JC et al (2014) Biodistribution and radiation dosimetry of the carbonic anhydrase IX imaging agent [(18) F]VM4-037 determined from PET/CT scans in healthy volunteers. Mol Imaging Biol 16:739–746
13. Aerts HJ, Dubois L, Perk L et al (2009) Disparity between in vivo EGFR expression and 89Zr-labeled cetuximab uptake assessed with PET. J Nucl Med 50:123–131
14. Dubois L, Douma K, Supuran CT et al (2007) Imaging the hypoxia surrogate marker CA IX requires expression and catalytic activity for binding fluorescent sulfonamide inhibitors. Radiother Oncol 83:367–373
15. Innocenti A, Vullo D, Scozzafava A, Supuran CT (2005) Carbonic anhydrase inhibitors. Inhibition of isozymes I, II, IV, V, and IX with anions isosteric and isoelectronic with sulfate, nitrate, and carbonate. Bioorg Med Chem Lett 15:567–571
16. Metwalli AR, Turkbey B, McKinney Y, et al (2014) Results of a phase II trial of novel carbonic anhydrase IX radiotracer 18F-VM4-037 in renal cell carcinoma. In 2014 Genitourinary Cancer Symposium. San Francisco
17. Zhao Z, Liao G, Li Y, Zhou S et al (2014) Prognostic value of carbonic anhydrase IX immunohistochemical expression in renal cell carcinoma: a meta-analysis of the literature. PLoS ONE 9:e114096
18. Liu Z, Pourghiasian M, Radtke MA et al (2014) An organotrifluoroborate for broadly applicable one-step (18) f-labeling. Angew Chem 53:11876–11880
19. Honarvar H, Garousi J, Gunneriusson E et al (2015) Imaging of CAIX-expressing xenografts in vivo using 99mTc-HEHEHE-ZCAIX:1 Affibody molecule. Int J Oncol 46:513–520